How taurine is produced
A biotransformation method converts O-acetyl-L-serine to taurine efficiently, addressing low yields in existing methods by using OAS sulfhydrylase and sulfite, resulting in a sustainable and economically viable production process.
Patent Information
- Application Number
- JP2024531729
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2021-11-29
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2041-11-29
AI Technical Summary
Current methods for producing taurine, such as those involving metabolic engineering, yield low amounts of taurine and require complex processing to extract it from cells, making them unsuitable for industrial use.
A biotransformation method using O-acetyl-L-serine (OAS) as a substrate, where OAS is converted to L-cysteic acid with OAS sulfhydrylase in the presence of sulfite, followed by decarboxylation to taurine using L-cysteine sulfinate decarboxylase, bypassing heterologous production strains.
This method produces taurine in high yields without the need for extreme conditions or harmful chemicals, making it sustainable and economically viable, with taurine being directly usable or easily enriched.
Smart Images

Figure 2024544052000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for producing taurine from O-acetyl-L-serine (OAS) by biotransformation, which comprises in a first process step (biotransformation 1) the production of L-cysteic acid from O-acetyl-L-serine (OAS) in the presence of sulfite using an enzyme selected from the class of OAS sulfhydrylases (EC 4.2.99.8) and then in a second process step (biotransformation 2) the decarboxylation of L-cysteic acid to taurine, which results from the biotransformation.
[0002] Taurine (2-aminoethanesulfonic acid, CAS number 107-35-7) is an aminosulfonic acid that occurs naturally as a breakdown product of the amino acids cysteine and methionine. Taurine is an ingredient in energy drinks and is also used in pet food, for example for cats and farmed fish (Salze and Davis (2015) Aquaculture 437: 215-229). However, taurine is also thought to have health-promoting properties (Ripps and Shen (2012), Molecular Vision 18: 2673-2686).
[0003] In nature, taurine is found almost exclusively in the animal kingdom, with only a few examples in bacteria, algae or plants. The biosynthetic pathways to taurine are diverse (for an overview, see, for example, "Taurine and hypotaurine metabolism" in the KEGG Pathway Database), starting in particular from L-cysteine. The most important steps in the synthesis of taurine from L-cysteine are shown in formulas (1)-(5). (1) L-cysteine + O 2 -> L-Cysteine Sulfinic Acid (2) L-cysteine sulfinic acid + 1 / 2O 2 -> L-cysteic acid (3) L-Cysteine sulfinic acid -> hypotaurine + CO 2 (4) Hypotaurine + 1 / 2O 2 -> Taurine (5) L-cysteic acid -> taurine + CO 2
[0004] (1) In the first step, L-cysteine is oxidized by the enzyme cysteine dioxygenase (CDO, EC 1.13.11.20) to L-cysteine sulfinic acid (3-sulfinoalanine, CAS number 207121-48-0). (2) Cysteine sulfinate oxidase (previously a rather hypothetical enzymatic step) further oxidizes L-cysteine sulfinate to L-cysteic acid ((R)-2-amino-3-sulfopropionic acid, CAS number 23537-25-9). (3) L-cysteine sulfinic acid is decarboxylated to hypotaurine (2-aminoethanesulfinic acid, CAS number 300-84-5) by cysteine sulfinic acid decarboxylase (CSAD, EC 4.1.1.29). (4) Hypotaurine is oxidized to taurine, a process that has not previously been adequately explained. (5) In a similar step to (3), L-cysteic acid is decarboxylated to taurine by the appropriate CSAD enzyme.
[0005] Currently, commercially used taurine is produced chemically. One known method, for example, that of Changshu Yudong Chemical Factory, starts with ethylene, then ethyleneimine, and finally taurine. The consumer-driven trend from chemically produced raw materials to sustainably produced raw materials has led to an increasing search for biotechnological methods for taurine production. Conventional techniques rely on metabolic engineering approaches to heterologously express suitable biosynthetic genes in producer strains to produce taurine or its biosynthetic precursor, hypotaurine.
[0006] Honjoh et al. (2010), Amino Acids 38: 173-1183, described a genetically engineered yeast strain heterologously expressing the CDO and CSAD genes from carp (Cyprinus carpio). When L-cysteine was added to the growth of the genetically engineered strain, hypotaurine was observed to be produced as the major product, along with a relatively small proportion of taurine. 2 O 2 When treated with L-cysteine, hypotaurine was oxidized to taurine. Although S. cerevisiae itself can produce cysteine from its own metabolism, exogenous L-cysteine had to be added to the growth medium to produce hypotaurine and taurine.
[0007] Tevatia et al. (2019), Algal Research 40:101491 similarly produced taurine in the algae Chlamydomonas reinhardtii using heterologously expressed CDO and CSAD genes from carp. The intracellular taurine yield was 0.14 mg taurine per g dry biomass.
[0008] Joo et al. (2018), J. Agric. Food Chem. 66:13454-13463, described a genetically engineered strain of the bacterium Corynebacterium glutamicum that produced 0.5 g / L of taurine when grown in shake flasks. It was clear that taurine was accumulated intracellularly and not secreted into the growth medium. The synthesis of taurine was achieved by heterologous expression in the strain of the genes for L-cysteine acid synthase, cysteine dioxygenase and L-cysteine sulfinic acid decarboxylase. In addition, repressor genes related to the biosynthesis of methionine and cysteine were inactivated, simultaneously improving sulfur absorption. In addition to the low yield, the fact that taurine is produced intracellularly seems to be a fundamental drawback in terms of product isolation. A complex disruption of the cells is necessary to release taurine for further processing.
[0009] WO17213142A1 (Ajinomoto) describes a taurine-producing strain obtained by heterologous expression of cysteine dioxygenase and L-cysteine sulfinic acid decarboxylase in a strain capable of producing cysteine. The main product is hypotaurine with a maximum yield of 450 μM, which can then be converted to taurine only in low yield by alkali treatment.
[0010] US9267148B2, US2012 / 0222148A1, US2018 / 0028474A1, US2019 / 0085339, WO2017 / 176277A1 and WO2019 / 094051 (Plant Sensory Systems) describe taurine producing strains and organisms that variously involve heterologous expression of cysteine dioxygenase and L-cysteine sulfinic acid decarboxylase. The main focus of these applications is the production of taurine in plants, but nothing is said about yields.
[0011] US20190062757A1 (KnipBio) describes heterologous production strains for producing taurine or its precursors.
[0012] The prior art has disclosed various metabolic engineering approaches to produce hypotaurine or taurine in heterologous production systems. Although the production yields from metabolic engineering approaches have been disclosed, the yields are too low for industrial use.
[0013] The prior art also provides methods for the production of non-proteinogenic (unnatural) amino acids, for example by direct microbial fermentation (EP1191106B1, Wacker) or by biotransformation of OAS catalyzed by O-acetyl-L-serine sulfhydrylase (OAS sulfhydrylase) (EP1247869B1, Wacker). These methods catalyze the reaction of OAS with a nucleophile to form a non-proteinogenic amino acid according to the general formula (6): (6) OAS + nucleophile -> unsaturated amino acid + acetic acid
[0014] In EP1247869B1 (Wacker) a number of different nucleophiles are tested for their suitability as nucleophiles for the reaction with OAS catalyzed by OAS sulfhydrylase, such as selenides, selenols, azides, cyanides, azoles and isoxazolinones. In addition, sulfur compounds from the group of thiosulfates and thiols of the general formula HSR are also used, where the radical R is a monovalent substituted or unsubstituted alkyl, alkoxy, aryl or heteroaryl radical.
[0015] These methods are not suitable for the production of L-cysteic acid and / or taurine.
[0016] The aim of the present invention is to provide a biotechnological method for producing taurine by biotransformation, bypassing heterologous production strains generated by metabolic engineering.
[0017] This object is achieved by a method for producing taurine from O-acetyl-L-serine (OAS) by biotransformation, which in a first process step (biotransformation 1) produces L-cysteic acid from O-acetyl-L-serine (OAS) in the presence of sulfite using an enzyme selected from the class of OAS sulfhydrylases (EC 4.2.99.8) and then in a second process step (biotransformation 2) decarboxylates L-cysteic acid to taurine.
[0018] As disclosed in the accompanying application Co12102 and in the examples of the present invention, it has been surprisingly found that sulfites (hereinafter referred to as sulfites or SO 3 2- It has been found that the nucleophile (referred to as "Aminothiocyanate") is suitable as a nucleophile in reaction (6) and, as an extension of EP1247869B1 (Wacker), allows the synthesis of the non-proteinogenic amino acid L-cysteic acid (biotransformation 1) in the previously unknown reaction of equation (7). (7) OAS+SO 3 2- -> L-cysteic acid + acetic acid
[0019] Also unexpectedly, L-cysteic acid produced in biotransformation 1 could be decarboxylated to taurine by the recombinantly produced CSAD enzyme according to equation (5) without further processing (biotransformation 2).
[0020] The advantage of the method for producing taurine of the present invention is that it is a sustainable, technically feasible and economically viable biotransformation method for producing taurine. No environmentally harmful chemicals are required. No fossil raw materials are consumed and no toxic chemical waste and / or waste gases are generated. Therefore, the production method of the present invention is environmentally friendly and sustainable. Furthermore, the method of the present invention does not require extreme reaction conditions or special equipment and is therefore technically easy to implement. There is an increasing demand for such a method.
[0021] The taurine from the method of the present invention can be used directly without further processing steps or can be concentrated by known methods.
[0022] In the context of the present invention a distinction is made between the following manufacturing processes: 1.Chemical method 2. Biotechnology Methods a) Metabolic engineering Metabolic engineering (also called "pathway design"), in contrast to biotransformation, is a biotechnological method of altering the metabolic pathways of an organism by optimizing or modifying genes and regulatory processes. New or modified enzymes can be introduced into an organism by supplementing the genome with the genes of the enzymes, or genes of endogenous enzymes can be expressed at enhanced or attenuated levels, thereby establishing new metabolic pathways in the organism or enhancing or attenuating existing metabolic pathways. The goal of metabolic engineering is to produce new metabolites or cell endogenous metabolites in higher yields in an organism. The metabolic engineering process does not use starting materials specific to the metabolites, such as enzyme substrates, e.g., OAS in the present invention, but instead only uses a nutrient medium, also called growth medium, that is necessary for the growth of the organism of interest and is composed of a carbon source (e.g., glucose), a nitrogen source (e.g., ammonium salts or complex amino acid mixtures such as peptones or yeast extract), and other salts necessary for growth. Such nutrient media are known to the skilled artisan from microbiological practice. b) Biotransformation Biotransformation is defined as the conversion of one or more reactants to products under enzyme catalysis, where the enzyme substrate is added to the reaction batch together with the enzyme. In the reaction batch, the added enzyme substrate, such as OAS or L-cysteic acid in the present invention, is enzymatically converted. In the present invention, this is achieved by an enzyme selected from the class of OAS sulfhydrylases (EC 4.2.99.8) in the presence of sulfite according to formula (7) for OAS, and by an enzyme selected from the class of cysteine sulfinic acid decarboxylases (CSAD, EC 4.1.1.29) for L-cysteic acid according to formula (5). The reactants can be derived from chemical or biotechnological production. The OAS used in the method of the present invention can be derived, for example, from chemical synthesis or from biotechnological production by fermentation of a production strain. The L-cysteic acid used in the method of the present invention is obtained, for example, from chemical synthesis or from biotechnological production by biotransformation of OAS. The enzymes used in the enzymatic catalysis can be obtained from biotechnological production, for example by growing a production strain by fermentation, or biological materials containing the enzymes (e.g. plants, fungi, algae, animal organs) are used. The biomass or biological materials from the growth of the production strain can be used as such, or the enzymes are isolated therefrom depending on the requirements of the biotransformation. The enzymes CysM and CSADcc used in the method of the invention can be obtained from biotechnological production by fermentation of the production strain.
[0023] In the context of the present invention, a reaction batch is defined as a mixture of reactants (starting materials), enzymes, and optionally other reactants, in which the reactants are converted into products.
[0024] The yield of a reaction in the sense of the present invention is defined as the amount of reactant used that is converted into product under the reaction conditions. The yield can be expressed as an absolute amount (g or mmol), a volumetric yield expressed in absolute amount of product per unit volume (mM or g / L), or a relative yield, also called percentage yield, expressed as the proportion of reactants used (taking into account the molecular weights of the reactants and products).
[0025] Fermentation is a process step for the production (cultivation) of cell cultures on an industrial scale, in which preferably microbial production strains are grown under defined conditions of medium, temperature, pH, oxygen supply and mixing of the medium. Depending on the composition (genetic composition) of the production strain, the aim of the fermentation is to produce proteins / enzymes or metabolic products, in each case in the highest possible yield for further use. The OAS, OAS sulfhydrylase and cysteine sulfinic acid decarboxylase, which are components of the method of the invention, can be produced by fermentation. The end product of fermentation is a fermentation broth consisting of the biomass of cells of the production strain (fermentation cells) and the fermentation medium (fermentation supernatant) removed from the biomass and formed from the growth medium and metabolic products secreted by the fermentation cells during fermentation. The target product of fermentation can be present in the fermentation cells or in the fermentation medium. For example, the OAS is contained in the fermentation medium, whereas the enzymes OAS sulfhydrylase and CSADcc are contained in the fermentation cells.
[0026] Open reading frame (ORF, synonymous with cds or coding sequence) refers to a region of DNA or RNA that begins with a start codon, ends with a stop codon, and codes for the amino acid sequence of a protein. ORFs are also called coding regions or structural genes.
[0027] A gene refers to a DNA section that contains all the basic information to produce biologically active RNA. A gene includes a DNA section that is transcribed to produce a single-stranded RNA copy, and expression signals involved in regulating this copying process. Expression signals include, for example, at least one promoter, a transcription start site, a translation start site, and a ribosome binding site (RBS). Terminators and one or more operators are additional possible expression signals.
[0028] mRNA, also called messenger RNA, is a single-stranded ribonucleic acid (RNA) that carries the genetic information for protein synthesis. mRNA provides assembly instructions for specific proteins in cells. mRNA molecules transmit the messages required for protein synthesis from the genetic information (DNA) to the ribosomes responsible for protein synthesis. Inside the cell, mRNA molecules are formed as transcripts of the sections of DNA that correspond to genes. The genetic information stored in DNA remains unchanged by this process.
[0029] Eukaryotic genes are mainly called mosaic genes, which, unlike prokaryotic genes, also contain non-coding regions called introns (intragenic regions). Coding sequences, called exons (expressed regions), are the portions of DNA in eukaryotic genes that are transcribed into RNA and then translated by ribosomes into the amino acid sequence of a protein. After DNA is transcribed into RNA, the introns are cut off from the primary transcript. The protein-coding RNA from which the introns have been removed is called messenger RNA (mRNA) or "mature" mRNA. It undergoes further modifications such as capping and polyadenylation. The coding region of the mature mRNA is then translated into a protein sequence. When eukaryotic genes containing exon / intron structures are expressed in prokaryotes, it is necessary to reverse translate the protein sequence or coding region of the mature mRNA into DNA that does not contain introns, since the processing of exon / intron structures does not occur in prokaryotes. In the context of the present invention, when referring to a gene sequence derived from a protein sequence or a gene sequence derived from an mRNA, it is precisely this process of reverse translation that is meant. Preferably, the protein or mRNA sequence is reverse-translated into a DNA sequence and at the same time optimised, ie adapted to the codon usage of the corresponding prokaryotic organism (codon optimisation).
[0030] A genetic construct refers to a DNA molecule in which a gene is linked to other genetic elements (promoters, terminators, selection markers, origins of replication, etc.). A genetic construct in the context of the present invention is a circular DNA molecule, called a plasmid, vector or expression vector. The genetic elements of the genetic construct cause its extrachromosomal inheritance during cell growth to produce the protein encoded by the gene.
[0031] The abbreviation WT (Wt) stands for wild type. A wild-type gene refers to the form of a gene that arises naturally through evolution and is present in the wild-type genome. The DNA sequence of the Wt gene is publicly available in databases such as NCBI.
[0032] Biotransformation 1: The method for producing taurine of the present invention requires the availability of OAS. Chemical methods for producing OAS can be, for example, by acetylation of L-serine, which is costly due to the high price of L-serine, or by the production of racemic O-acetyl-D / L-serine, which can be used directly, or OAS can be obtained in advance from the racemate, for example, by dissolution. In the case of direct acetylation, N-acetyl-L-serine (NAS) can be formed as a by-product, for example, by non-selective acetylation of the hydroxyl or amino groups of L-serine, or the known rearrangement of OAS to NAS at neutral to alkaline pH values (Tai et al. (1995), Biochemistry 34: 12311-12322), which either results in a reduced yield or requires the prior introduction of a protecting group on the amino group of L-serine. Thus, direct acetylation of L-serine is not practical for an economically viable process.
[0033] Biotechnological production of OAS is known. This involves the use of organisms in which cysteine metabolism is deregulated, thereby providing high levels of OAS. A fermentation process for producing OAS is disclosed in EP1233067B1 (WACKER) and described in Example 1 of the present invention.
[0034] The production of OAS using Escherichia coli is preferred, and it is particularly preferred to use Escherichia coli, which is deposited under the number DSM 13495 at the DSMZ-German Collection of Microorganisms and Cell Cultures GmbH (Braunschweig) according to the Budapest Treaty.
[0035] An advantage of the present invention is that the OAS-containing fermentation broth, e.g. obtained from a fermentation carried out according to EP 1233067, can be used directly as fermentation supernatant after removing the particulate biomass, e.g. by centrifugation, as a source of OAS in the process of the invention without further post-treatment, purification or isolation steps, including extraction, adsorption, ion exchange chromatography, precipitation or crystallization. This procedure is particularly economical and avoids the isolation of unstable compounds.
[0036] A person skilled in the art can use isotopic analysis to determine whether a substance such as OAS or L-cysteic acid that one wishes to use in the method of the present invention is derived from chemical or fermentative production. Differentiable isotopic analysis methods are described, for example, in Sieper et al., Rapid Commun. Mass Spectrom. (2006) 20: 2521-2527 and are based on, for example, measuring the isotope ratios of carbon and nitrogen, which differ depending on whether the product is produced chemically (petroleum-based) or fermentatively (from plant-based raw materials).
[0037] OAS sulfhydrylases have been isolated from various plants and microorganisms. For example, Escherichia coli has two OAS sulfhydrylase enzymes, named CysK and CysM, and the related genes are also known and named cysK and cysM, respectively.
[0038] OAS sulfhydrylases in the sense of the present invention are characterized in that they are able to catalyze the synthesis of the proteinogenic amino acid L-cysteine from OAS according to formula (8), where the nucleophile used is sulfide. Thus, both CysM-related enzymes and CysK-related enzymes are OAS sulfhydrylases in the sense of the present invention. (8) OAS+S 2- -> L-cysteine + acetic acid
[0039] Both enzymes have very similar reaction mechanisms and are involved in the biosynthesis of L-cysteine, but unlike CysK, CysM has a variable substrate spectrum with respect to the nucleophiles that can react with OAS according to equation (6). For example, it is known that, unlike CysK, CysM can catalyze the reaction of OAS with thiosulfate to form S-sulfocysteine (CAS number 1637-71-4). This reaction plays an important role in the growth of bacteria that use thiosulfate as the sole sulfur source. Furthermore, EP1247869B1 (Wacker) discloses the use of CysM for the production of non-proteinogenic amino acids.
[0040] Preferably, the method according to the invention is characterized in that the OAS sulfhydrylase is a bacterial enzyme, particularly preferred is CysM, especially preferred is CysM from an Escherichia coli strain.
[0041] The CysM-containing OAS sulfhydrylase is characterised in that it is produced by fermentation, particularly preferably by fermentation of an E. coli strain, particularly preferably by fermentation of the E. coli strain DH5α / pFL145.
[0042] Example 2 discloses a procedure for the fermentative biotechnological production of CysM using the strain E. coli DH5α / pFL145. The production strain consists in this case of a host strain, such as E. coli DH5α, and a suitable genetic construct for expressing OAS sulfhydrylase, preferably the genetic construct pFL145. The host strain and the genetic construct as well as the production of the production strain are described in EP1247869B1. The production strain has been deposited according to the Budapest Treaty at the DSMZ-German Collection of Microorganisms and Cell Cultures GmbH, Braunschweig, under the number DSM14088.
[0043] The fermentation broth obtained by fermentation of the production strain consists of fermentation cells containing the OAS sulfhydrylase and a fermentation medium (fermentation supernatant). In the method of the invention, the fermentation broth can be used as is without further treatment or, alternatively, a suspension of fermenter cells, for example in a buffer solution (resuspension fermenter cells), can be used after separation from the fermentation broth, for example by centrifugation or filtration. Example 2 describes the production of resuspended CysM-containing fermentation cells of the E. coli DH5α / pFL145 strain.
[0044] It is further contemplated that the OAS sulfhydrylase is used in the form of a cell homogenate after mechanical disruption of the fermentation cells, or in the form of chemically permeabilized cells (e.g., with chloroform), or as a cell extract after removal of particulate matter from the cell homogenate, or as an enzyme purified by chromatography or the like. It is preferred that the OAS sulfhydrylase is used as a fermentation broth without further treatment, as a cell suspension of resuspended fermenter cells, or as a cell homogenate after mechanical disruption of the resuspended fermenter cells, or in the form of chemically permeabilized cells (e.g., with chloroform). It is particularly preferred that the OAS sulfhydrylase is used in the form of resuspended fermentation cells, or as a cell homogenate. It is particularly preferred that resuspended fermentation cells of an OAS sulfhydrylase-producing strain are used.
[0045] In the method of the present invention, OAS reacts with sulfite under the catalysis of OAS sulfhydrylase to form L-cysteic acid according to equation (7).
[0046] Sulfite forms multiple species that exist simultaneously in reversible equilibrium, and the suitability of each as a nucleophile in the biotransformation of the present invention was unpredictable. 2 SO 3 ) is gaseous SO 2 As a dibasic acid, it exists in different equilibria depending on the pH of the aqueous solution, and it is known that the species in the equilibrium also differ in their suitability as nucleophiles. The following equilibria (9) to (13) are known. (9)SO 2 (Gas) <-> SO 2 (dissolution) (10)SO 2 (dissolution)+H2O <-> H 2 SO 3 (11)H 2 SO 3 <-> HSO 3 - +H + (12)HSO 3 - <->SO 3 2- +H + (13)2HSO 3 - <-> S 2 O 5 2- +H 2 O
[0047] Sulfurous acid and its salts are used as preservatives in the food industry because they exhibit antibacterial properties. This means that sulfurous acid and its salts can kill microorganisms, which is due to the inactivation of enzymes necessary for the survival of microorganisms. Therefore, a person skilled in the art would expect that the CysM enzyme would also be inactivated when sulfurous acid or its salts are used, and L-cysteic acid would not be produced by the method disclosed in EP1247869B1.
[0048] It was surprising to those skilled in the art that sulfite and OAS could be used in biotransformation to produce L-cysteic acid as a starting compound for a biotechnological process to produce taurine.
[0049] In principle, all possible salts of sulfite are suitable for this reaction. Preferably, the method of the invention is carried out in such a way that the salt of sulfite used is Na 2 SO 3 , K 2 SO 3 , (NH 4 ) 2 SO 3 , NaHSO 3 (or its anhydrous Na 2 S 2 O 5 ) or KHSO 3 Particularly preferably, the sulfite used is Na 2 SO 3 , NaHSO 3 (or its anhydrous Na 2 S 2 O 5 ) or (NH 4 ) 2 SO 3 and particularly preferably Na 2 SO 3 or NaHSO 3 (or its anhydrous Na 2 S 2 O 5 ).
[0050] It is possible to use gaseous sulfur dioxide, which is the anhydride of sulfurous acid. When this is introduced into the reaction batch, sulfurous acid H 2 SO 3 Depending on the pH, it forms hydrated and deprotonated forms HSO 3 - and S.O. 3 2- and reaches equilibrium.
[0051] Preferably, the method according to the invention is characterized in that the concentration of sulfite is at least equimolar to the OAS, particularly preferably at least a 1.5-fold molar excess of sulfite, particularly preferably at least a 5-fold molar excess.
[0052] In a particularly preferred embodiment, the method for producing taurine is characterized in that both the OAS sulfhydrylase and the OAS are produced by fermentation.
[0053] OAS as a reactant in the biotransformation process according to the invention isomerizes to N-acetyl-L-serine (NAS) from a pH of about 7, which is then unsuitable for reaction with sulfite to form L-cysteic acid. The mechanism of the reaction has been studied in Tai et al. (1995), Biochemistry 34: 12311-12322, and involves an intramolecular nucleophilic attack by the deprotonated amino group on the carbonyl carbon of the acyl radical. This reaction is inhibited with decreasing pH, so that the compound is stable, for example, at pH 4.0.
[0054] Thus, the biotransformation process according to the present invention is preferably characterized in that the reaction is carried out under pH conditions that minimize the isomerization of OAS to NAS.
[0055] The reaction temperature of the biotransformation 1 is preferably selected between 5° C. and 70° C. Preferred reaction temperatures are between 10° C. and 60° C., particularly preferred are reaction temperatures between 15° C. and 50° C., and particularly preferred are reaction temperatures between 20° C. and 40° C.
[0056] The OAS concentration in the batch is preferably at least 1 g / L, particularly preferably at least 10 g / L, particularly preferably at least 40 g / L.
[0057] In the biotransformation of OAS, the molar yield of L-cysteic acid, based on the molar amount of OAS used, is preferably at least 60%, particularly preferably at least 70%, particularly preferably at least 80%.
[0058] In a further preferred embodiment of the biotransformation process 1, the substrate OAS is metered from a reservoir into a reaction batch consisting of OAS sulfhydrylase and sulfite in a so-called feed process (Example 5). Isomerization of OAS to NAS in the OAS-containing reservoir is preferably avoided by setting a pH of ≦6.5, particularly preferably a pH of ≦6.0, particularly preferably a pH of ≦5.5. At the same time, the pH in the reaction batch is adjusted to favor the reaction forming L-cysteic acid, preferably a pH of ≦7.5, particularly preferably a pH of ≦7.0, particularly preferably a pH of ≦6.5.
[0059] According to equation (7), in the reaction to form L-cysteic acid from OAS, a stoichiometric amount of acetic acid is released, which leads to a decrease in the pH in the batch as the reaction proceeds. Since an excessively low pH affects the activity of OAS sulfhydrylase, priority should be given to preventing an excessively large decrease in pH. This can be done passively by an appropriate high concentration buffer in the batch or achieved actively by a measurement and control unit.
[0060] Particularly preferred is active pH control by a measurement and control unit, as disclosed in Example 5, which restores the desired pH by metered addition of alkaline solution or acid if the pH deviates from the target value (the so-called pH-stat method).
[0061] Biotransformation 1 can be carried out in discontinuous or continuous operation. In discontinuous operation (batch operation), all reactants are added to the batch in the middle of the reaction and the batch is processed after the reaction is completed. In continuous operation, OAS, CysM enzyme and sulfite are constantly metered in during the reaction and the solution containing the product L-cysteic acid is simultaneously removed from the batch. A steady state is established in which the reactants are metered in so that they can react completely during the residence time in the reaction vessel to form the product L-cysteic acid. A method for the continuous production of unnatural amino acids is disclosed, for example, in EP1247869B1 (Wacker). Biotransformation 1 is preferably a discontinuous process.
[0062] Biotransformation 2: The method for producing taurine of the present invention comprises biotransformation 1 to produce L-cysteic acid, and then biotransformation 2 to decarboxylate L-cysteic acid to produce taurine.
[0063] The decarboxylation of cysteic acid to taurine can be carried out chemically or by enzymatic catalysis in biotransformations. Thermal decarboxylation at high temperatures with metal catalysts, which is considered unsustainable, is known but has the disadvantages of being energy intensive and producing a high proportion of by-products.
[0064] Preferably, the method of the invention is characterized in that L-cysteic acid is decarboxylated to taurine using an enzyme from the class of L-cysteine sulfinic acid decarboxylase (CSAD, EC 4.1.1.29), aspartate 1-decarboxylase (EC 4.1.1.11), or glutamic acid decarboxylase (EC 4.1.1.15).
[0065] For the enzymatically catalyzed decarboxylation of L-cysteic acid to taurine, enzymes of the L-cysteine sulfinic acid decarboxylase (CSAD, EC 4.1.1.29) class are particularly preferred. CSAD enzymes are known to decarboxylate L-cysteine sulfinic acid to hypotaurine according to formula (3). These enzymes are also able to decarboxylate L-cysteic acid as a substrate to taurine, to a lesser extent, according to formula (5). As disclosed in Examples 7-11, for example, the CSADcc enzyme from Cyprinus carpio is suitable for decarboxylating L-cysteic acid to taurine.
[0066] The enzyme of class EC4.1.1.29 (CSAD) is found mainly in metazoa (multicellular animals), including mammals. Enzymes with CSAD activity are also found in unicellular organisms, such as algae of the genus Synechoccocus, and bacteria or fungi. Preferably, the method for producing taurine of the present invention is characterized by using the CSAD enzyme of class EC4.1.1.29 from mammals selected from human (Homo sapiens), cow (Bos taurus), rat (Rattus norvegicus) or mouse (Mus musculus), and fish such as carp (Cyprinus carpio), particularly preferably from human (Homo sapiens), rat (Rattus norvegicus) or carp (Cyprinus carpio).
[0067] Particularly preferred is the CSAD enzyme from carp (CSADcc, Cyprinus carpio). In the examples, a CSADcc enzyme is used which is derived from the protein sequence of the Wt CSAD enzyme from Cyprinus carpio, called CSADcc, and which has the DNA sequence of the cds, called CSADcc cds, disclosed in nt 31-1530 of SEQ ID NO: 1, and which encodes a protein having the amino acid sequence of SEQ ID NO: 2.
[0068] The DNA sequence forming the basis of the Wt CSADcc amino acid sequence is available in the NCBI (National Center for Biotechnology Information) database under GenBank sequence ID: AB220585.1 (cds: nt 82-1584). Derived from the corresponding Wt CSADcc amino acid sequence is the CSADcc cds DNA sequence (nt 31-1530 of SEQ ID NO: 1) which is codon-optimized for expression in E. coli and encodes the same amino acid sequence. For codon optimization, publicly available software programs are available, such as Eurofins Genomics GENEius software used in Example 6. The DNA of SEQ ID NO: 1 is synthesized by known methods provided by commercial companies such as Eurofins Genomics.
[0069] Particularly preferably, the L-cysteine sulfinic acid decarboxylase is SEQ ID NO: 2 or a sequence homologous to this sequence.
[0070] A homologous sequence is understood to mean that the DNA or amino acid sequences are at least 80%, preferably at least 90%, particularly preferably at least 95% identical, and each modification in the homologous sequence is selected from insertions, additions, deletions and substitutions of one or more nucleotides or amino acids.
[0071] The degree of DNA identity is determined by the "nucleotide blast" program based on the blastn algorithm at http: / / blast.ncbi.nlm.nih.gov / . The algorithm parameters used to align two or more nucleotide sequences are the default parameters. The default general parameters are: Max target sequences=100; Short queries="Automatically adjust parameters for short input sequences"; Expect Threshold=10; Word size=28; Automatically adjust parameters for short input sequences=0. The corresponding default scoring parameters are: Match / Mismatch Scores=1, -2, Gap Costs=Linear.
[0072] Protein sequences are compared using the "protein blast" program at http: / / blast.ncbi.nlm.nih.gov / . This program uses the blastp algorithm. The algorithm parameters used to align two or more protein sequences are the default parameters. The default general parameters are: Max target sequences=100; Short queries="Automatically adjust parameters for short input sequences"; Expect Threshold=10; Word size=3; Automatically adjust parameters for short input sequences=0. The default scoring parameters are: Matrix=BLOSUM62; Gap Costs=Existence:11 Extension: 1; Compositional adjustments=Conditional compositional score template adjustment.
[0073] Preferably, the method of the invention is characterized in that the L-cysteine sulfinic acid decarboxylase is derived from fermentative production. The recombinant production of the corresponding CSADcc enzyme in an E. coli production strain is disclosed in Example 6. For this purpose, the CSADcc cds are cloned in a known manner into an expression vector, for example the vector pKKj, generating the genetic construct pCSADcc-pKKj (Figure 1). The production strain is produced by transforming the genetic construct pCSADcc-pKKj into an E. coli host strain, for example the E. coli JM105 strain, also in a known manner, and using the resulting production strain E. coli JM105 x pCSADcc-pKKj to produce the CSADcc enzyme, also in a known manner. The CSADcc enzyme can be produced on a shake flask scale for laboratory purposes or by fermentation (Example 6).
[0074] The CSAD enzyme contains pyridoxal phosphate (PLP, CAS number 54-47-7) as a cofactor. Therefore, supplementing the growth medium or biotransformation batch for converting L-cysteic acid to taurine with PLP is one way to achieve process improvement. Since PLP belongs to the vitamin B6 family, supplementing with other members of the vitamin B6 family, such as pyridoxine (CAS number 65-23-6), pyridoxal (CAS number 66-72-8) or pyridoxamine (CAS number 85-87-0), is a suitable alternative for process improvement. Preferably, the biotransformation process for converting L-cysteic acid to taurine is characterized in that it is carried out in the presence of ≧20 mg / L PLP, particularly preferably ≧10 mg / L, particularly preferably ≧4 mg / L.
[0075] In the method of the invention, the CSAD enzyme, preferably CSADcc, obtained by growth or fermentation in shake flasks can be used as fermentation broth without further processing or as cell suspension after reisolation of the cells, for example by centrifugation and resuspension of the fermented cells in a buffer (resuspended fermented cells).Furthermore, the CSAD enzyme, preferably CSADcc, can be used in the form of a cell homogenate after mechanical disruption of the resuspended fermented cells, or in the form of chemically permeabilized cells (for example with chloroform), or as a cell extract after removal of particulate components from the cell homogenate, or as purified enzyme, for example by chromatography.
[0076] The CSAD enzyme (CSADcc) is preferably used as a fermentation broth without further processing, as resuspended fermentation cells, or as a cell homogenate after mechanical disruption of resuspended fermentation cells. Particularly preferably, the CSAD enzyme is used as a resuspended fermentation cell, or as a cell homogenate after mechanical disruption of resuspended fermentation cells. Particularly preferably, the CSAD enzyme is used in the form of resuspended fermentation cells.
[0077] The biotransformation of L-cysteic acid to taurine by a CSAD enzyme, preferably CSADcc, is preferably carried out under pH and temperature conditions that allow efficient decarboxylation of L-cysteic acid to taurine.
[0078] The preferred pH range in which biotransformation 2 is carried out is pH 5.0 to 9.0, particularly preferred is pH 6.0 to 8.5, and particularly preferred is pH 6.5 to 8.0.
[0079] Biotransformation 2 is preferably carried out at temperatures below 70°C, preferably below 60°C, particularly preferably below 50°C, particularly preferably below 40°C.
[0080] The molar yield of taurine from the biotransformation of cysteic acid is preferably at least 60%, particularly preferably at least 80%, particularly preferably at least 90%.
[0081] The biotransformation of cysteic acid to produce taurine can be carried out in discontinuous or continuous operation. In discontinuous (batch) operation, all reactants are added to the batch during the reaction and the batch is processed after the reaction is completed. In continuous operation, the CSAD enzyme is introduced as stationary phase, for example immobilized on a membrane reactor or support, and the substrate L-cysteic acid is metered in as mobile phase. The contact time between the mobile phase and the stationary phase is set so that the substrate L-cysteic acid is completely reacted to form the product taurine. Discontinuous (batch) operation is preferred.
[0082] A preferred process for producing taurine from OAS, including biotransformation 1 and biotransformation 2, is characterized in that it comprises the following steps: a) OAS is produced by fermentation, b) enzymes of the class of OAS sulfhydrylases (EC 4.2.99.8), such as CysM, and the class of cysteine sulfinic acid decarboxylases (EC 4.1.1.29), such as CSADcc, are produced by fermentation; c) OAS and sulfurous acid or sulfite react under enzymatic catalysis by OAS sulfhydrylase of point b to form L-cysteic acid; d) L-cysteic acid at point c is decarboxylated to taurine by the CSAD enzyme at point b.
[0083] Particularly preferably, the method comprising steps a, b, c and d comprises, in biotransformation 1, converting OAS to Na in a CysM-catalyzed reaction. 2 SO 3 or its anhydrous salt Na 2 S 2 O 5 to form L-cysteic acid, and in biotransformation 2, the L-cysteic acid from biotransformation 1 is decarboxylated to taurine in a CSAD-catalyzed biotransformation according to formula (5). These method steps are disclosed in Examples 7-10. For this purpose, the OAS of biotransformation 1 can be produced synthetically or by growth of a production strain, as described in Example 1 of the present invention. It is preferred to produce the OAS by growth of a production strain. The CysM enzyme of biotransformation 1 can be obtained from fermentation of a production strain, as described in Example 2. The CSAD enzyme used in biotransformation 2 can be obtained from growth of a production strain, preferably the CSADcc enzyme from growth of the E. coli JM105×pCSADcc-pKKj strain, as described in Example 6. The L-cysteic acid from biotransformation 1 can be used in biotransformation 2 without further workup or after prior workup, as described in Examples 8-10. The skilled artisan is familiar with various methods for this purpose, such as filtration, centrifugation, extraction, adsorption, ion exchange chromatography, precipitation, crystallization, etc. In biotransformation 2, it is preferable to use L-cysteic acid from biotransformation 1 without further workup.
[0084] The method for producing taurine simply and efficiently combines a previously undescribed method for the enzymatic production of L-cysteic acid from OAS and sulfite (also called sulfurous acid) according to equation (7) (Biotransformation 1) with the enzymatic decarboxylation of L-cysteic acid to taurine according to equation (5) (Biotransformation 2). That is, the present invention is a two-step biotransformation method combining Biotransformation 1 and Biotransformation 2 for the production of taurine from OAS.
[0085] Preferably, the process steps for the preparation of taurine (biotransformation 1 and biotransformation 2) proceed continuously, i.e. one after the other. If the process comprises steps a-d of the already described preferred embodiment, an alternative preferred embodiment is characterized in that all of the process steps are carried out in one reaction batch. If all of the process steps are carried out in one reaction batch, the process is also called a one-pot process or one-pot reaction. This has the advantage that all reactants for the preparation of taurine are already present in the reaction batch or can be simply metered in. Carrying out the process in one reaction batch is particularly important in view of the economic feasibility.
[0086] For example, according to the disclosure of Example 11 of the present invention, the method steps can be carried out in one batch (one-pot process), where OAS reacts with sulfite (salt of sulfurous acid) in the presence of enzymes CysM and CSADcc. L-cysteic acid is produced in the first reaction according to equation (7) and is decarboxylated to taurine "in situ" by CSADcc according to equation (5).
[0087] The product distribution of L-cysteic acid and taurine from the reaction of OAS in one-pot process is determined by the activity of CysM on CSADcc. If CSADcc is added in sufficient amount, the L-cysteic acid formed from OAS can be quantitatively converted to taurine. The method of converting the OAS used to L-cysteic acid and taurine is preferred. The total molar yield of L-cysteic acid and taurine based on the molar amount of OAS used is preferably 60% or more, particularly preferably 70% or more, particularly preferably 80% or more. The molar yield of taurine based on the molar amount of OAS used is preferably 25% or more, particularly preferably 50% or more, particularly preferably 80% or more.
[0088] For a one-pot process, it is conceivable that the genes for OAS sulfhydrylase and L-cysteine sulfinic acid decarboxylase could be co-expressed in one strain and cells from the growth of that strain could be reacted with OAS in the presence of sulfite for biotransformation to produce taurine as the end product.
[0089] In one variation of the invention, in the context of a metabolic engineering approach, it is contemplated that genes for OAS sulfhydrylase and L-cysteine sulfinic acid decarboxylase are expressed in OAS producing strains and taurine is produced by growth of such producing strains in the presence of sulfite (salt of sulfurous acid).
[0090] The figure shows the plasmids used in the examples. [Brief description of the drawings]
[0091] [Figure 1] pCSADcc-pKKj
[0092] Abbreviations used in the drawings: AmpR: a gene that confers ampicillin (β-lactamase) resistance Ori: origin of replication Ptac:tac promoter ECoRI: Restriction enzyme ECoRI cleavage site HindIII: Restriction enzyme HindIII cleavage site CSADcc: CSAD (cysteine sulfinic acid decarboxylase) C.carpio cds EXAMPLES
[0093] The present invention is further illustrated by the following non-limiting examples.
[0094] Example 1: Preparation of OAS The strain E. coli W3110 / pACYC-cysEX-GAPDH-ORF306 was used, described in EP1233067B1 (WACKER) and deposited under number DSM13495 at the DSMZ-German Collection of Microorganisms and Cell Cultures GmbH (Braunschweig) according to the Budapest Treaty. OAS was produced by fermentation as described in EP1233067B1. At the end of the fermentation, OAS was stabilized by setting the pH to 4.5 with 21% (v / v) phosphoric acid. Cells were removed by centrifugation (Heraeus Megafuge 1.0 R) at 4000 rpm for 10 min. The OAS content in the fermentation supernatant, determined by HPLC, was 15.3 g / L.
[0095] HPLC analysis of cysteic acid and taurine: The quantification of the compounds analyzed in the examples employed HPLC methods calibrated for OAS, L-cysteic acid and taurine, respectively. All reference substances used for calibration were commercial products (Sigma-Aldrich). An Agilent 1260 Infinity II HPLC system was used, equipped with a unit from the same manufacturer for pre-column derivatization with o-phthaldialdehyde (OPA derivatization), as known for the analysis of amino acids. The HPLC system was equipped with a fluorescence detector to detect the OPA derivatization products OAS, L-cysteic acid and taurine. The detector was set at an excitation wavelength of 330 nm and an emission wavelength of 450 nm. Also, a Thermo Scientific™ Accucore™ aQ column Scientific, 100 mm long, 4.6 mm inner diameter, 2.6 μm particle size, thermally equilibrated at 40° C. in the column oven was used.
[0096] Eluent A: 25 mM sodium phosphate, pH 6.0. Eluent B: methanol. Separation was performed in gradient mode: 10% eluent B to 60% eluent B over 0-25 min, then 60% eluent B to 100% eluent B over 2 min, then 100% eluent B for another 2 min at a flow rate of 0.5 ml / min. Retention time of L-cysteic acid: 3.2 min. Retention time of taurine: 14.8 min. Retention time of OAS: 17.0 min.
[0097] Example 2: Production of the enzyme CysM The E. coli DH5α / pFL145 strain was used, as described in EP1247869B1 (Wacker) and deposited according to the Budapest Treaty at the DSMZ-German Collection of Microorganisms and Cell Cultures GmbH (Braunschweig) under number DSM 14088. The CysM enzyme was produced both by growth in shake flasks and by fermentation. A) Growth in shake flasks: A preculture of E. coli strain DH5α / pFL145 was prepared in Lbamp medium (10 g / l tryptone (GIBCO™), 5 g / l yeast extract (BD Biosciences), 5 g / l NaCl, 100 mg / L ampicillin (Sigma-Aldrich)) (grown overnight at 37° C. and 120 rpm). 25 ml of the preculture was used as inoculum for the main culture of 250 ml of LBamp medium (1 L Erlenmeyer flask with baffles). The main culture was shaken at 30° C. and 110 rpm. After 4 h, the cell density OD 600 reached 1.0 / ml (OD 600 The cell density per ml of cell suspension was photometrically determined by absorbance measurement at 600 nm; Genesys™ 10S UV-Vis spectrophotometer from Thermo Scientific™). The inducer tetracycline (Sigma-Aldrich, final concentration 3 mg / L) was then added and the culture was continued for another 20 hours at 30° C. and 110 rpm. The cell density OD at the end of the culture was 600 was 3 / ml. B) Fermentative production of CysM using E. coli strain DH5α / pFL145 is disclosed in EP1247869B1. Cells from the fermentation were removed by centrifugation (Heraeus Megafuge 1.0 R) at 4000 rpm for 10 min, suspended in KPi6.5 buffer (0.1 M K phosphate, pH 6.5) and assayed at cell density OD 600 The concentration was adjusted to 90 / ml.
[0098] Cells grown or fermented in shake flasks were separated by centrifugation (15000 rpm for 10 min, Sorvall RC5C centrifuge with SS34 rotor) for further use. The cell pellet was resuspended in KPi6.5 buffer as a cell suspension for further use in the production of cell homogenates as described below. The cell suspension was prepared by centrifugation at a cell density of OD 600 Prepare a sample with enough KPi6.5 buffer to give an OD of 30 / ml: 60050 ml of cells from a shake flask culture with an OD of 3 / ml were centrifuged and resuspended in 5 ml of KPi6.5 buffer (10x concentration) or 600 One ml of cells from a fermentation with a .DELTA. of 90 / ml was resuspended in 3 ml of KPi6.5 buffer (3-fold dilution).
[0099] This resulted in cells of E. coli strain DH5α / pFL145 being produced, isolated from the fermentation broth, resuspended, and used as the OAS sulfhydrylase CysM in the method of the present invention.
[0100] To prepare the cell homogenate, a FastPrep-24™ 5G cell homogenizer from MP Biomedicals was used. Cell density OD 600 One ml of cell suspension in KPi6.5 buffer with a lysing rate of 30 / ml was disrupted in a manufacturer-assembled 1.5 ml tube containing glass beads ("Lysing Matrix B") (3 x 20 seconds at a shaking frequency of 6000 rpm with a 30 second pause between each interval). The resulting cell homogenate was used directly as OAS sulfhydrylase (CysM enzyme) in the method of the present invention or for the preparation of cell extracts.
[0101] To prepare the cell extract, the resulting cell homogenate was centrifuged (15,000 rpm for 10 min in a Sorvall RC5C centrifuge with a SS34 rotor) and the supernatant was referred to as the cell extract and was used as the OAS sulfhydrylase (CysM enzyme) in the method of the present invention or further used for measuring the CysM enzyme activity.
[0102] The protein content of the cell extracts was measured using the Qubit® Protein Assay Kit on a Qubit3.0 Fluorometer from Thermo Fisher Scientific. The protein content of the cell extract from the shake flask culture was 5.3 mg / ml. The protein content of the cell extract from the fermentation was 4.0 mg / ml.
[0103] CysM enzyme activity was measured as described in EP1247869B1 (Wacker). For this purpose, OAS (Sigma-Aldrich) was diluted with Na 2 The assay was incubated at 37°C in the presence of cell extracts from growth of S. coli and E. coli DH5α / pFL145 strains. Assays in KPi6.5 buffer (final volume 0.4 ml) contained 10 mM OAS (added from a 200 mM stock solution in 500 mM sodium succinate buffer, pH 5.5), 10 mM sodium sulfide, 2 S, and 5 μl of CysM-containing cell extract. Cysteine produced in the CysM reaction was measured using ninhydrin (Sigma-Aldrich) according to the method of Gaitonde (1967), Biochem. J. 104: 627-633. The CysM enzyme activity in the cell extract of shake flask-cultured E. coli DH5α / pFL145 strain was 57.1 U / ml. The OD of shake flask-cultured cells was 1.2 μg / ml. 600 The enzyme activity of the shake flask cultured cells was 5.7 U / ml because the OD of the fermented cells (OD 3 / ml) was concentrated 10-fold for the preparation of the cell extract. The CysM enzyme activity in the cell extract after fermentation of E. coli DH5α / pFL145 was 58.1 U / ml. The fermented cells (OD 600 90 / ml) was used for the preparation of cell extracts. 600 The OD was diluted to 30 / ml, so the concentration of fermented cells (OD 600 The enzyme activity in the cell suspension was 174.4 U / ml.
[0104] The specific CysM enzyme activity of the cell extract of E. coli DH5α / pFL145 strain was 10.8 U / mg protein. The enzyme activity of the cell extract after fermentation of the specific CysM E. coli DH5α / pFL145 strain was 14.5 U / mg. Assuming that the CysM activity was completely released from the cells during the preparation of the cell extract, the CysM enzyme activity measured in the cell extract was comparable to the enzyme activity present in the CysM cell suspension in the following examples.
[0105] 1U / ml CysM enzyme activity corresponds to the concentration of OAS and Na in 1 ml of cell extract under assay conditions. 2 This means that 1 μmol of cysteine is produced per minute from S (volume activity). The specific CysM enzyme activity in U per mg of protein is obtained by dividing the volume activity of the cell extract (U / ml) by the protein concentration of the cell extract (mg / ml) and is defined as the CysM enzyme activity in U based on 1 mg of protein in the cell extract.
[0106] Example 3: Commercial OAS and Na using CysM produced in shake flask cultures 2 SO 3 Production of L-cysteic acid from Two batches were run in parallel. Batch 1: First, put 8.25 ml of NaPi6.5 buffer (50 mM sodium phosphate, pH 6.5) into a 100 ml Erlenmeyer flask, and then add 0.2 M Na in NaPi6.5 buffer. 2 SO 3 1 ml of solution, 0.4 ml of CysM cell extract from shake flask culture (Example 2A) with an activity of 57.1 U / ml (final concentration in the batch of 2.3 U / ml), and 350 μl of a 0.2 M OAS×HCl (Sigma-Aldrich) solution in 0.5 M sodium succinate, pH 5.5 were added sequentially. The batch volume was 10 ml. Batch 2: Batch (Na 2 SO 3 Batch 2 (control batch not containing Na) had the same composition as Batch 1. 2 SO 3 Instead of the solution, 1 ml of NaPi6.5 buffer was added.
[0107] Both batches were incubated at 37°C and 140 rpm in a chest shaker (Infors). After 1 and 3 hours, 1 ml of each batch was incubated at 80°C for 5 min to stop the reaction, centrifuged, and the supernatants were analyzed by HPLC. The amount of L-cysteic acid detected by HPLC is shown in Table 1.
[0108] [Table 1]
[0109] Example 4: OAS-containing culture supernatant and Na from fermentations using CysM produced in shake flask cultures 2 SO 3 Production of L-cysteic acid from In a 100 ml Erlenmeyer flask, 1 ml of cell culture supernatant from the fermentation of E. coli W3110 / pACYC-cysEX-GAPDH-ORF306 strain with an OAS content of 15.3 g / L (from Example 1) was placed, followed by 6 ml of NaPi6.5 buffer, 1 M Na in NaPi6.5 buffer, and 1 ml of 1 M Na 2 SO 3 solution, and 2 ml of CysM cell suspension from shake flask growth (cell density OD from Example 2A). 600 30 / ml, CysM enzyme activity 57.1 U / ml) were added sequentially. The batch volume was 10 ml. CysM enzyme activity in the batch was 11.4 U / ml. The batch was incubated at 37°C and 140 rpm in a chest shaker (Infors). After 2 h, 1 ml of the batch was incubated at 80°C for 5 min, centrifuged and the supernatant was analyzed by HPLC to determine OAS and L-cysteic acid content. The progress of the reaction over time is summarized in Table 2.
[0110] [Table 2]
[0111] Example 5: Preproduction of L-cysteic acid by biotransformation of OAS at constant pH A 0.5 L thermostated double-walled glass vessel (Diehm) was connected via a hose connection to a thermostat (Lauda) and the temperature was adjusted to 37°C.
[0112] First, 50 ml (OD ) of a CysM-containing cell suspension in KPi6.5 buffer from a fermentation of strain DH5α / pFL145 (from Example 2B) was 600 90 / ml, CysM enzyme activity 8720U) and Na in KPi6.5 buffer 2 S 2 O5 6.6 ml (13.9 mmol, molecular weight 190.1 g / mol) of a 400 g / L solution of NaHSO 3 (1.78-fold molar excess over the 15.6 mmol of OAS that was metered in later). The batch was stirred with a magnetic stirrer. The batch was also equipped with a pH electrode (Mettler Toledo), which was connected to a pH control unit (TitroLine α titrator, Schott) and operated in pH-stat mode according to the manufacturer's instructions. Under pH-stat conditions, the pH in the reaction vessel was kept constant at a set pH of 6.5 for the entire duration of the reaction by metering in 2 M NaOH from a burette connected to the control unit. 150 ml of OAS-containing cell culture supernatant (OAS content: 15.3 g / L, 2.3 g, 15.64 mmol) from the fermentation of E. coli W3110 / pACYC-cysEX-GAPDH-ORF306 strain (Example 1) was metered into the batch from a reservoir via a pump (Watson Marlow 101U / R peristaltic pump) at a flow rate of 0.35 ml / min.
[0113] The reaction time was 19 hours. The batch was carried out in an open reaction vessel, so the batch volume at the end of the reaction was 185 ml due to evaporation. Aliquots of 1 ml were taken from the batch at 0.5, 3 and 19 hours after the start of the reaction and the L-cysteic acid content was analyzed by HPLC. The time course of L-cysteic acid production is summarized in Table 3. After 19 hours of reaction time, the L-cysteic acid content in the batch was 12,970 mg / L (76.65 mM), which corresponds to an absolute molar yield of L-cysteic acid of 14.18 mmol for a batch volume of 185 ml. Based on the amount of OAS used, 15.64 mmol, this corresponds to a yield of 90.1%.
[0114] [Table 3]
[0115] Example 6: Recombinant production of CSADcc from Caprinus carpio (carp) in Escherichia coli Vector pCSADcc-pKKj: The cDNA gene (cDNA: complementary DNA, isolated from mRNA by reverse transcription) of cysteine sulfinic acid decarboxylase (CSAD) from carp (Cyprinus carpio) was isolated by Honjoh et al. (2010), Amino Acids 38: 1173-1183, and the DNA sequence is published in the NCBI (National Center for Biotechnology Information) database as GenBank sequence ID: AB220585.1 (cds: nt82-1584). The corresponding amino acid sequence was used to derive a DNA sequence (published Eurofins Genomics GENEius software) that was codon-optimized for expression in E. coli and synthetically generated (Eurofins Genomics). The synthesized DNA had the sequence disclosed in SEQ ID NO: 1 and contained the cds of the gene (hereinafter referred to as CSADcc). cds (SEQ ID NO:1, nt 31-1530) has the amino acid sequence disclosed in SEQ ID NO:2 and encodes a protein called CSADcc. For cloning purposes, the synthesized DNA had an ECoRI cleavage site (SEQ ID NO:1, nt 25-30) at the 5' end and a HindIII cleavage site (SEQ ID NO:1, nt 1532-1537) at the 3' end.
[0116] The vector pCSADcc-pKKjcds (Figure 1), suitable for recombinant expression of CSADcc, was generated by cleaving the synthetic DNA with ECoRI and HindIII and cloning it as an ECoRI / HindIII fragment in known manner into the vector pKKj cleaved with ECoRI and HindIII. The expression vector pKKj disclosed in EP2670837A1 (Wacker) is a derivative of the expression vector pKK223-3. The DNA sequence of pKK223-3 is disclosed in the GenBank gene database under the accession number M77749.1. Approximately 1.7 kb (bp 262 to 1947 of the DNA sequence disclosed in M77749.1) was removed from the 4.6 kb plasmid to obtain the 2.9 kb expression vector pKKj.
[0117] E. coli JM105xpCSADcc-pKKj production strain: The CSADcccds were expressed in E. coli by transforming the vector pCSADcc-pKKj by known methods into the E. coli K12JM105 strain, which is commercially available from DSMZ-German Collection of Microorganisms and Cell Cultures GmbH under strain number DSM3949.
[0118] Clones from the transformation were selected on LBamp plates, which contained 10 g / l tryptone (GIBCO™), 5 g / l yeast extract (BD Biosciences), 5 g / l NaCl, 15 g / l agar, and 100 mg / L ampicillin (Sigma-Aldrich). Clones were selected for growth and fermentation in shake flasks. The CSADcc producing strain was named E. coli JM105×pCSADcc-pKKj. The CSADcc cds were expressed in E. coli JM105×pCSADcc-pKKj in a known manner under the control of an IPTG-inducible tac promoter (IPTG: isopropyl β-thiogalactoside, Sigma-Aldrich) and operably linked to the CSADcc cds.
[0119] Growth in shake flasks: A preculture of E. coli JM105 × pCSADcc-pKKj strain was prepared in LBamp medium (growth overnight at 37°C and 120 rpm, Infors chest shaker).
[0120] Two ml of the preculture was used as inoculum for the main culture of 100 ml of SM3 medium (1 L Erlenmeyer flask) supplemented with 15 g / L glucose, 5 mg / L pyridoxal phosphate (PLP, Sigma-Aldrich), and 100 mg / L ampicillin. The main culture was shaken at 30°C and 140 rpm in a chest shaker (Infors). After 4 h of incubation time, the cell density OD 600The inducer IPTG (Sigma-Aldrich, final concentration 0.4 mM) was then added and growth continued for an additional 20 h at 30° C. and 140 rpm in a chest shaker (Infors).
[0121] Composition of SM3 medium: 12g / L K 2 HPO 4 , 3g / L KH 2 PO 4 , 5g / L (NH 4 ) 2 SO 4 , 0.3 g / L MgSO 4 x7H 2 O, 0.015 g / L CaCl 2 ×2H 2 O, 0.002 g / L FeSO 4 x7H 2 O, 1 g / L Na 3 Citrate x 2H 2 O, 0.1 g / L NaCl, 5 g / L peptone (Oxoid), 2.5 g / L yeast extract (BD Biosciences), 0.005 g / L vitamin B1, and 1 ml / L trace element solution.
[0122] Composition of trace element solution: 0.15g / L Na 2 MoO 4 2H 2 O, 2.5 g / L H 3 BO 3 , 0.7 g / L CoCl 2 6H 2 O, 0.25 g / L CuSO 4 5H 2 O, 1.6 g / L MnCl 2 4H 2 O, 0.3 g / L ZnSO 4 7H 2 O.
[0123] Cells from shake flask cultures were separated by centrifugation. Cell suspensions were prepared by resuspending the cell pellet from 50 ml of shake flask culture in 2 ml of 50 mm sodium phosphate, pH 7.0 (NaPi 7.0 buffer). The cell suspensions were either used directly in biotransformation studies or used to prepare cell homogenates.
[0124] To prepare cell homogenates, a FastPrep-24™ 5G cell homogenizer from MP Biomedicals was used: 2×1 ml of cell suspension was disrupted in a manufacturer-assembled 1.5 ml tube containing glass beads ("Lysing Matrix B") (3×20 s at a shaking frequency of 6000 rpm, with a 30 s pause between each interval).
[0125] The resulting cell homogenate (2 ml volume) was used for the biotransformation of L-cysteic acid to taurine without further treatment.
[0126] Fermentative growth: The production strain E. coli JM105xpCSADcc-pKKj was used for the fermentation. The fermentation was carried out in a Biostat B fermenter (working volume 2 L) from Sartorius BBI Systems GmbH.
[0127] Shake flask preculture: In a 1-L Erlenmeyer flask, 100 ml of LBamp medium was inoculated from the agar medium containing the JM105 × pCSADcc-pKKj strain, and cultured in an incubation shaker (Infors) at 30°C and 120 rpm for 7 to 8 hours to obtain a cell density (OD 600 The cells were cultured until the number of cells reached 2-4 / ml.
[0128] Fermenter: 1.5 L of FM2 medium supplemented with 40 g / L glucose and 100 mg / L ampicillin was inoculated with 21.3 ml of the shake flask preculture. Fermentation conditions were: temperature 30°C, constant pH 7.0 (25% NH 4 OH and 6.8N H 3 PO 4automatic compensation for 0.05% (automatic compensation for 0.05%), foam control by automatic metered addition of 4% v / v Struktol J673 (Schill & Seilacher) in water, stirrer speed 450–1300 rpm, constant aeration with sterile filtered compressed air at 1.7 vvm (vvm: the amount of compressed air introduced into the fermentation batch expressed as liters of compressed air per liter of fermentation volume per minute), pO 2 ≥ 50%. 2 is controlled by the agitation speed, and after 16 h of fermentation time, the cell density OD 600 reached 45 / ml.
[0129] Production fermenter: 150 ml of pre-fermentor culture was inoculated into 1.35 L of FM2 medium at pH 7.0 supplemented with 20 g / L glucose, 0.36 g / L pyridoxine (vitamin B6, Sigma-Aldrich), and 100 mg / L ampicillin. Fermentation conditions were: temperature 30°C, constant pH 7.0 (25% NH 4 OH and 6.8N H 3 PO 4 (automatic compensation by 0.01ppm), foam control by automatic metered addition of 4% v / v Struktol J673 (Schill & Seilacher) in water, stirrer speed 450-1300 rpm, constant aeration 1.7 vvm, pO 2 ≥ 50%. 2 was adjusted by the stirrer speed. The fermentation time was 30 hours.
[0130] FM2 medium: 5 g / L (NH 4 ) 2 SO 4 , 0.50g / L NaCl, 0.075g / L FeSO 4 x7H 2 O, 1 g / L Na 3 Citrate, 0.30 g / L MgSO 4 x7H 2 O, 0.015 g / L CaCl 2 ×2H 2 O, 1.50 g / L KH 2 PO 4, 0.005 g / L vitamin B1 (Sigma-Aldrich), 5.00 g / L peptone (Oxoid), 2.50 g / L yeast extract (Oxoid), and 0 ml / L trace element solution (equivalent to that used for shake flask culture).
[0131] First, the pH in the fermentation tank was adjusted to 25% NH 4 The pH was adjusted to 7.0 by injecting OH solution. During fermentation, the pH was adjusted to 7.0 with 25% NH 4 OH or 6.8N H 3 PO 4 The oxygen probe was maintained at a value of 7.0 by automatic correction by . For inoculation, 150 ml of preculture was injected into the fermenter vessel. The initial volume was therefore 1.5 L. The culture was first stirred at 350 rpm and aerated with an aeration rate of 1.7 vvm. Under these starting conditions, the oxygen probe was calibrated to 100% saturation before inoculation.
[0132] O during fermentation 2 Saturation (pO 2 ) was set at 50%. 2 After the saturation falls below the target value, O 2 A control cascade was initiated to bring the saturation back to the target value, in conjunction with which the stirring speed was continuously increased (up to a maximum of 1300 rpm).
[0133] Fermentation was carried out at a temperature of 30° C. When the glucose content in the fermenter dropped from the initial 20 g / L to about 5 g / L, a 60% (w / w) glucose solution was metered in continuously. The feed rate was adjusted so that the glucose concentration in the fermenter did not exceed 2 g / L thereafter. Glucose was measured using a glucose analyzer from YSI (Yellow Springs, Ohio, USA).
[0134] O.D. 600 When the cell density OD reached 50 / ml (8 h fermentation time), the inducer IPTG (final concentration 0.2 mM) was added once to start the expression of the CSADcc gene. The fermentation was stopped 22 h after induction, i.e., 30 h total fermentation time. At this point, the cell density OD 600was 164 / ml. One liter of fermentation broth was centrifuged (15,000 rpm for 10 min, Sorvall RC5C centrifuge equipped with SS34 rotor), the fermentation supernatant was discarded, and the cells were resuspended in 1 L of NaPi7.0 buffer and stored in 50 ml aliquots at -20°C for further use.
[0135] Example 7: Production of taurine by biotransformation of commercially available L-cysteic acid 12mg L-cysteic acid x H 2 0 (Sigma-Aldrich) was weighed into a 100 ml Erlenmeyer flask and dissolved in 9.7 ml of NaPi7.0 buffer. The reaction was started by the addition of 0.3 ml of cell homogenate from shake flask growth of JM105×pCSADcc-pKKj (Example 6). The batch volume was 10 ml. L-Cysteic Acid×H 2 The molar concentration of O was 6.41 mM (L-cysteic acid × H 2 The batch was incubated at 37°C and 140 rpm on a chest shaker (Infors). After 3 hours, 1 ml of the batch was incubated at 80°C for 5 minutes, centrifuged and the supernatant was analyzed by HPLC. The L-cysteic acid used was completely consumed. The amount of taurine produced was 789.4 mg / L, which corresponds to a molar content of 6.31 mM (molecular weight of taurine: 125.1 g / mol). The molar yield of taurine produced from 6.41 mM L-cysteic acid x HO was therefore 98.4%.
[0136] Example 8: Production of taurine by biotransformation from commercially available OAS Response 1: Production of L-cysteic acid from OAS: In a 100 ml Erlenmeyer flask, first 6.6 ml of KPi6.5 buffer was placed, followed by 0.4 ml of a stock solution of 0.2 M OAS×HCl (Sigma-Aldrich) dissolved in 0.5 M sodium succinate (pH 5.5), 1 M Na in KPi6.5 buffer, and 2 SO 3and 2 ml of cell suspension of cysM cells from shake flask growth (from Example 2A, CysM enzyme activity 57.1 U / ml) were added subsequently. The batch volume was 10 ml. The amount of CysM enzyme in the batch was 11.4 U / ml. The molar concentration of OASxHCl was 8.00 mM (1.47 g / L, molecular weight of OASxHCl: 183.6 g / mol). The batch was incubated at 37°C and 140 rpm on a chest shaker (Infors). After 3 hours, 1 ml of the batch was incubated at 80°C for 5 min, centrifuged and the supernatant was analyzed by HPLC. The OAS used was completely consumed. The amount of L-cysteic acid produced was 1350.4 mg / L, corresponding to a molar content of 7.98 mM (molecular weight of L-cysteic acid: 169.2 g / mol). The molar yield of L-cysteic acid produced from 8.00 mM OAS×HCl was 99.7%.
[0137] Response 2: Formation of taurine from L-cysteic acid synthesized in reaction 1: A 9 ml batch of reaction 1 was placed in a 100 ml Erlenmeyer flask, the pH was adjusted to 7.0 with 1 M KOH, and 1 ml of cell homogenate from shake flask growth of strain JM105×pCSADcc-pKKj was added (Example 6). The batch volume was 10 ml. The L-cysteic acid content from reaction 1 was 1350.4 mg / L, and the L-cysteic acid content at the start of reaction 2 was 1215.4 mg / L (7.18 mM with a molecular weight of L-cysteic acid of 169.2). The batch was incubated at 37° C. and 140 rpm on a chest shaker (Infors). After 3 hours, 1 ml of the batch was incubated at 80° C. for 5 min, centrifuged and the supernatant was analyzed by HPLC. The L-cysteic acid used was completely consumed. The taurine content was 825.7 mg / L (6.60 mM with the molecular weight of taurine being 125.1 g / mol). The molar yield of taurine produced from 7.18 mM L-cysteic acid was 91.9%.
[0138] Example 9: Fermentative production of OAS and NaHSO 3 and taurine production by CSADcc-catalyzed conversion of L-cysteic acid from the reaction with fermentatively produced CysM enzyme In a 100 ml Erlenmeyer flask, 7 ml of NaPi7.0 buffer containing 5 mg / L L-PLP, 1 ml of the batch of Example 5 with an L-cysteic acid content of 12,970 mg / L, and 2 ml of CSADcc cells (Example 6) in NaPi7.0 buffer were mixed. The batch volume was 10 ml. The L-cysteic acid content in the batch was 1,297 mg / L, corresponding to a molar content of 7.67 mM (molecular weight of L-cysteic acid: 169.2 g / mol). The batch was incubated at 37° C. and 140 rpm on a chest shaker (Infors). After 4 hours, 1 ml of the batch was incubated at 80° C. for 5 minutes, centrifuged and the supernatant was analyzed by HPLC. The L-cysteic acid used was completely consumed. The amount of taurine produced was 925.3 mg / L, corresponding to a molar content of 7.40 mM (molecular weight of taurine: 125.1 g / mol). The molar yield of taurine produced from 7.67 mM L-cysteic acid was 96.4%.
[0139] Example 10: Preproduction of taurine Biotransformation 1: A 0.5 L thermostated double-walled glass vessel (Diehm) was connected via a hose connection to a thermostat (Lauda) and the temperature was adjusted to 37°C.
[0140] First, 50 ml (OD ) of CysM-containing cell suspension in KPi6.5 buffer from the fermentation of strain DH5α / pFL145 (Example 2) was 600 90 / ml, CysM enzyme activity 8720U) and Na in KPi6.5 buffer 2 S 2 O 5 20 ml of a 400 g / L solution (42.1 mmol, molecular weight 190.1 g / mol) of NaHSO 3(a 1.63-fold molar excess over the 51.7 mmol of OAS metered in later). The batch was stirred with a magnetic stirrer. The batch was also equipped with a pH electrode (Mettler Toledo), which was connected to a pH control unit (TitroLine α titrator, Schott) and operated in pH-stat mode according to the manufacturer's instructions. Under pH-stat conditions, the pH in the reaction vessel was kept constant at a set pH of 6.5 for the entire duration of the reaction by metering in 2 M NaOH from a burette connected to the control unit. 400 ml of OAS-containing fermentation supernatant (OAS content: 19.1 g / L, 7.6 g, 51.7 mmol) from the fermentation of E. coli W3110 / pACYC-cysEX-GAPDH-ORF306 strain (Example 1) was metered into the batch from a reservoir at a flow rate of 0.2 ml / min via a pump (Watson Marlow 101U / R peristaltic pump). The total reaction time was 46 h. The batch volume at the end of the reaction was 500 ml. After 1 h, 3 h, 20 h, 28 h and 46 h from the start of the reaction, 1 ml aliquots were taken in each case from the batch, incubated at 80° C. for 5 min, centrifuged and the supernatants were analyzed by HPLC to determine the content of L-cysteic acid. The formation of L-cysteic acid over time is summarized in Table 4. After 46 hours of reaction time, the L-cysteic acid content in the batch was 15,370 mg / L (90.8 mM), which corresponds to an absolute molar yield of L-cysteic acid of 45.4 mmol for a batch volume of 500 ml. Based on the amount of OAS used of 51.7 mmol, this corresponds to a yield of 87.8%.
[0141] [Table 4]
[0142] Biotransformation 2: A 0.3 L thermostated double-walled glass vessel (Diehm) was connected via a hose connection to a thermostat (Lauda) and the temperature was adjusted to 37°C.
[0143] 100 ml of L-cysteic acid-containing biotransformation 1 was adjusted to pH 7.0 with 2.5 M NaOH. 2 1 ml of 1 M DTE (dithioerythritol, Sigma-Aldrich) dissolved in O, 1 ml of 500 mg / L LPP dissolved in NaPi7.0 buffer (final concentration 4 mg / L) and 20 ml of CSADcc-containing fermented cells resuspended in NaPi7.0 buffer were added. The batches were stirred with a magnetic stirrer. The batch volume was 122 ml. At the start of the reaction and after 2, 4, 6 and 24 hours, in each case 1 ml aliquots were taken from the batch, incubated at 80 °C for 5 min, centrifuged and the supernatants were analyzed by HPLC for L-cysteine and taurine content. The results are summarized in Table 5. Based on the molar amount of L-cysteic acid used in the batch of 74.4 mM, the taurine yield (8.8 g / L, 70.2 mM) was 94.3%.
[0144] [Table 5]
[0145] Example 11: Production of taurine from OAS by a "one-pot reaction" The reaction batch was prepared by adding 3 ml of KPi6.5 buffer, 2 ml of OAS-containing fermentation supernatant from the fermentation of E. coli strain W3110 / pACYC-cysEX-GAPDH-ORF306 (Example 1), 1 M Na in KPi6.5 buffer, and 1 ml of ethanol. 2 SO 3 The batch consisted of 1 ml of CysM-containing cells from fermentation of strain DH5α / pFL145 (Example 2B), 2 ml of a cell suspension of CysM-containing cells from shake flask growth of strain JM105xpCSADcc-pKKj (Example 6). The batch volume was 10 ml. The OAS concentration in the batch was 3.1 g / L (20.80 mM). The Na 2 SO 3 The concentration was 100 mM. The CysM enzyme activity in the batch was 34.9 U / ml.
[0146] The reaction was carried out at pH 6.5. The batches were incubated at 37°C and 140 rpm on a chest shaker (Infors). 24 hours after the start of the reaction, 1 ml of the batch was incubated at 80°C for 5 min, centrifuged and the supernatant was analyzed by HPLC. The L-cysteic acid content was 1.3 g / L (7.68 mM with a molecular weight of L-cysteic acid of 169.2 g / mol). The taurine content was 721 mg / L (5.76 mM with a molecular weight of taurine of 125.1 g / mol). The molar yield of 7.68 mM L-cysteic acid produced from 20.80 mM OAS was 36.9%. The molar yield of 5.76 mM taurine produced from 20.80 mM OAS was 27.7%. Overall, the molar yield of L-cysteic acid and taurine produced from OAS was 64.6%.
Claims
1. A method for producing taurine from O-acetyl-L-serine (OAS) by biotransformation, comprising: i) in the first step (biotransformation 1), the production of L-cysteic acid from O-acetyl-L-serine (OAS) using an enzyme selected from the class of OAS sulfhydrylases (EC 4.2.99.8) in the presence of sulfite, followed by ii) in a second step (biotransformation 2), L-cysteic acid is decarboxylated to taurine; The method.
2. The method of claim 1 , wherein the OAS sulfhydrylase is a bacterial enzyme.
3. The method according to claim 1 or 2, wherein the OAS sulfhydrylase is derived from fermentation production.
4. The method of any one of claims 1 to 3, wherein the concentration of the sulfite is at least equimolar to the OAS.
5. 5. The method according to claim 1, wherein L-cysteic acid is decarboxylated to taurine using an enzyme from the class of L-cysteine sulfinic acid decarboxylase (EC 4.1.1.29), aspartate 1-decarboxylase (EC 4.1.1.11) or glutamate decarboxylase (EC 4.1.1.15).
6. The method of claim 5, wherein said L-cysteine sulfinic acid dedecarboxylase is SEQ ID NO: 2 or a sequence homologous thereto.
7. The method according to claim 5 or 6, wherein the L-cysteine sulfinic acid dedecarboxylase is derived from fermentation production.
8. a) OAS is produced by fermentation; b) enzymes of the class OAS sulfhydrylase (EC 4.2.99.8) and the class cysteine sulfinic acid decarboxylase (EC 4.1.1.29) are produced by fermentation; c) OAS and sulfite react under enzymatic catalysis by OAS sulfhydrylase of point b to form L-cysteic acid; d) L-cysteic acid at point c is decarboxylated to taurine by the CSAD enzyme at point b; The method according to any one of claims 1 to 7.
9. 9. The method according to claim 8, wherein all process steps are carried out in one reaction batch.
10. The method according to any one of claims 1 to 9, wherein the molar yield of taurine from the biotransformation of L-cysteic acid in biotransformation 2 is preferably at least 60%.
Citation Information
Patent Citations
Heterologous expression of taurine in microorganisms
WO2017083351A1
